Search results
Results from the WOW.Com Content Network
Unknowns include whether CBD raises concerns for specific populations like elderly individuals or pregnant people. And little is known about long-term use of the substance.
From 2015 to November 2022, the FDA issued dozens of warning letters to American manufacturers of CBD products for false advertising and illegal interstate marketing of CBD as an unapproved drug to treat diseases, such as cancer, osteoarthritis, symptoms of opioid withdrawal, Alzheimer's disease, and pet disorders. [58]
A study found that CBD significantly reduced anxiety during a simulated public speaking test for individuals with social anxiety disorder. However, the relationship between cannabis use and anxiety symptoms is complex, and while some users report relief, the overall evidence from observational studies and clinical trials remains inconclusive.
CBD may show antipsychotic and neuroprotective properties, acting as an antagonist to some of the effects of THC. Studies examining this effect have used high ratios of CBD to THC, and it is unclear to what extent these laboratory studies translate to the types of cannabis used by real life users.
CBD oil safety: A woman who ingested large doses of hemp oil to relieve stress had to be hospitalized in what may be a cautionary tale about herbal supplements.
The product pages for both Gentle Wave and Vigorvita CBD Gummies are both registered to an address in Reykjavik, Iceland, and calls to the registrant’s Iceland phone number were not answered.
Cannabis edibles with CBD can decrease symptoms of psychosis and anxiety. [25] Edible oils, tinctures, pills, and gummies have been prescribed to people with cancer to potentially improve poor appetite, pain, or weight loss. [27] Cannabis edibles may be effective for muscle spasms and pain. [28]
Nabiximols has also been studied for cancer pain resistant to opioids. While adjuvant use of nabiximols was safe in 3 trials for cancer pain, [ 22 ] [ 23 ] [ 24 ] data regarding efficacy were mixed, and the drug failed to meet its primary endpoint for this purpose in its first Phase III trial.